Syntara Limited to Host Investor Webinar on July 28, 2026, Highlighting Clinical Pipeline Updates and Quarterly Financial Results

Syntara's Clinical Pipeline and Drug Development Programs

Syntara Limited is a clinical-stage drug developer with expertise in targeting extracellular matrix dysfunction through advanced amine oxidase chemistry and complementary technologies. Its diversified clinical pipeline addresses multiple therapeutic areas including blood cancers, inflammatory conditions, and fibrotic diseases, aiming to meet significant unmet medical needs across various patient populations.

The company’s lead candidate, amsulostat (also known as SNT-5505 and formerly PXS-5505), is being developed for myelofibrosis—a bone marrow cancer characterized by scar tissue buildup leading to reduced blood cells. Amsulostat has received FDA Orphan Drug Designation and Investigational New Drug clearance, along with Fast Track Designation to potentially expedite development. The Phase 2a trial in myelofibrosis, testing the drug alone and combined with a JAK inhibitor, has been completed, validating its therapeutic potential.

Advancing into Myelodysplastic Syndrome with Early-Stage Trials

Following success in myelofibrosis, Syntara has launched two Phase 1c/2 studies of amsulostat in patients with myelodysplastic syndrome, another form of blood cancer. This expansion highlights confidence in the drug’s mechanism and broadens its clinical application. These early-stage trials evaluate safety and preliminary efficacy, providing critical data to guide further development and potential commercial opportunities.

The transition from myelofibrosis to myelodysplastic syndrome trials reflects a strategic effort to maximize amsulostat’s value. Investors will monitor initial safety outcomes and efficacy signals from these studies, which could support future advancement plans.

Topical Anti-Fibrotic Initiatives Targeting Scar Tissue Disorders

In addition to systemic therapies, Syntara is progressing a topical pan-LOX inhibitor program with SNT-9465 in a Phase 1a/b study targeting hypertrophic scars. This dermatological approach leverages the company's amine oxidase expertise to address significant clinical challenges in scar management by delivering treatment directly to affected tissues with reduced systemic exposure.

Moreover, Syntara continues collaboration with Professor Fiona Wood and the University of Western Australia on SNT-6302 for keloid scars. This partnership enhances scientific credibility and taps into specialized wound healing knowledge. Keloid scars pose a notable unmet need, especially in populations prone to abnormal scarring. The combined company-led and academic programs demonstrate a comprehensive strategy against fibrotic skin disorders.

Development of SNT-4728 for Neuroinflammation and Neurodegenerative Disorders

Syntara is advancing SNT-4728, a leading SSAO/MAO-B inhibitor under investigation for sleep disorders and to slow progression of neurodegenerative diseases such as Parkinson’s disease. By targeting neuroinflammation, a key factor in these conditions, the program aims to improve symptoms and disease outcomes. This initiative is conducted in collaboration with Parkinson’s UK, integrating patient advocacy and expertise to enhance clinical development.

This focus on central nervous system disorders represents a strategic expansion, addressing sleep disturbances common in Parkinson’s and related diseases. SNT-4728’s dual targeting of symptoms and underlying pathology positions it as a promising candidate. The partnership with Parkinson’s UK supports patient recruitment and trial design.

Expanding Portfolio Across Fibrotic and Inflammatory Diseases

Syntara’s pipeline also includes candidates targeting fibrotic and inflammatory diseases such as kidney fibrosis, metabolic dysfunction-associated steatohepatitis (MASH), pulmonary fibrosis, and cardiac fibrosis. This broad portfolio reflects the company’s expertise in extracellular matrix dysfunction, a shared pathological feature across multiple organs and diseases.

Fibrosis is a major unmet medical need in nephrology, hepatology, pulmonology, and cardiology. Conditions like idiopathic pulmonary fibrosis and cardiac fibrosis post-myocardial infarction have limited treatment options. Syntara’s approach offers novel mechanisms by addressing extracellular matrix dysfunction, potentially benefiting multiple indications. Success in one fibrotic disease could accelerate development across others.

Previous Commercial Respiratory Products and Strategic Divestment

Previously, Syntara operated commercially with two respiratory products: Bronchitol, a mucoactive therapy for cystic fibrosis, and Aridol, a lung function test agent. In October 2023, the company divested these assets, marking a strategic shift towards focusing exclusively on its clinical-stage pipeline and core scientific strengths.

The sale provided capital to support ongoing development programs and allowed management to concentrate resources on drug development. This restructuring aligns with common biotech strategies to prioritize high-potential clinical assets and optimize resource allocation, offering investors important context on the company’s current direction.

Investor Webinar Details and Participation Information

The investor webinar is scheduled for Tuesday, 28 July 2026 at 11am AEST, with CEO Gary Phillips presenting updates and an investor briefing. This event follows recent announcements and the Appendix 4C Quarterly Report release, providing comprehensive insights into clinical progress and financial status. Shareholders and investors can register via the provided Zoom link, receiving confirmation and dial-in details for phone participation.

Investors may submit questions live during the webinar or in advance to [email protected], accommodating varied schedules and promoting engagement. A replay will be available shortly after the live session at the same link, ensuring broad access to the update and management commentary.

Strategic Timing Aligned with Quarterly Financial Reporting

The webinar’s timing coincides with the release of Syntara’s Appendix 4C Quarterly Report, an ASX requirement detailing cash flow and financial position. This integrated update enables investors to assess clinical developments alongside financial metrics such as cash runway and burn rate.

Management will discuss the implications of the financial data for clinical programs and capital allocation, providing transparency on funding strategy and operational priorities. For clinical-stage biotech companies, understanding financial health is critical to evaluating the sustainability of development plans.

Company Overview and Australian Research Base

Syntara Limited (ABN: 75 082 811 630) is listed on the Australian Securities Exchange under ticker SNT. Headquartered and incorporated in Australia, the company’s management and scientific discovery teams operate from Sydney, leveraging world-class expertise and a supportive regulatory environment.

The Sydney location benefits from access to leading universities and research institutions specializing in chemistry, pharmacology, and clinical research, facilitating collaborations and scientific innovation. The Australian base ensures compliance with ASX listing standards and regulatory requirements for clinical trials. More information is available at www.syntaraTX.com.au.